Rearranged during Transfection (RET) Inhibitors
- Name
- Rearranged during Transfection (RET) Inhibitors
- Accession Number
- DBCAT005515
- Description
Not Available
- Drugs
Drug Drug Description Selpercatinib A RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations. Pralsetinib A RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer. - Drugs & Drug Targets